Second patient death in Pfizer’s DMD gene therapy studies renews safety concerns

The death of a young boy in a Phase II study of Pfizer’s DMD gene therapy candidate fordadistrogene movaparvovec again raises questions about the safety of a drug class that has yet to definitively demonstrate efficacy.

In a letter from Pfizer Inc. (NYSE:PFE) to the Duchenne muscular dystrophy community, which was posted on the Parent Project Muscular Dystrophy (PPMD) website, the pharma reported that a young boy participating in the Phase II DAYLIGHT study of fordadistrogene movaparvovec had died...